SG11201810018TA - Phosphoramidate nucleoside derivatives as anticancer agents - Google Patents
Phosphoramidate nucleoside derivatives as anticancer agentsInfo
- Publication number
- SG11201810018TA SG11201810018TA SG11201810018TA SG11201810018TA SG11201810018TA SG 11201810018T A SG11201810018T A SG 11201810018TA SG 11201810018T A SG11201810018T A SG 11201810018TA SG 11201810018T A SG11201810018T A SG 11201810018TA SG 11201810018T A SG11201810018T A SG 11201810018TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cardiff
- cladribine
- pct
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609601.8A GB201609601D0 (en) | 2016-06-01 | 2016-06-01 | Phosphoramidate compounds |
| PCT/GB2017/051549 WO2017207986A1 (en) | 2016-06-01 | 2017-05-31 | Phosphoramidate nucleoside derivatives as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810018TA true SG11201810018TA (en) | 2018-12-28 |
Family
ID=56410850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810018TA SG11201810018TA (en) | 2016-06-01 | 2017-05-31 | Phosphoramidate nucleoside derivatives as anticancer agents |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10906929B2 (ru) |
| EP (1) | EP3464309B1 (ru) |
| JP (2) | JP7025351B2 (ru) |
| KR (1) | KR20190015353A (ru) |
| CN (1) | CN109195981A (ru) |
| AU (1) | AU2017273117B2 (ru) |
| BR (1) | BR112018074961A2 (ru) |
| CA (1) | CA3025440A1 (ru) |
| CL (1) | CL2018003404A1 (ru) |
| DK (1) | DK3464309T3 (ru) |
| EA (1) | EA036409B1 (ru) |
| ES (1) | ES2801448T3 (ru) |
| GB (1) | GB201609601D0 (ru) |
| HR (1) | HRP20200983T1 (ru) |
| HU (1) | HUE051335T2 (ru) |
| IL (1) | IL263121B (ru) |
| MX (1) | MX2018014859A (ru) |
| MY (1) | MY198880A (ru) |
| PH (1) | PH12018502606A1 (ru) |
| PL (1) | PL3464309T3 (ru) |
| PT (1) | PT3464309T (ru) |
| SA (1) | SA518400552B1 (ru) |
| SG (1) | SG11201810018TA (ru) |
| SI (1) | SI3464309T1 (ru) |
| WO (1) | WO2017207986A1 (ru) |
| ZA (1) | ZA201807652B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| IL291927A (en) | 2014-11-28 | 2022-06-01 | NuCana plc | Oligonucleotides containing modified nucleosides |
| US11180484B2 (en) | 2016-05-31 | 2021-11-23 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| RS63069B1 (sr) | 2017-11-29 | 2022-04-29 | Kalvista Pharmaceuticals Ltd | Dozni oblici koji sadrže inhibitor kalikreina plazme |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| KR102665499B1 (ko) * | 2018-03-09 | 2024-05-14 | 메디비르 아베 | (2,2-비스하이드록시메틸)메틸렌사이클로프로판 뉴클레오티드로의 암 치료 |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| CN110845560B (zh) * | 2019-11-21 | 2021-08-24 | 广东中科药物研究有限公司 | 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1309525A2 (en) * | 2000-07-13 | 2003-05-14 | Micrologix Biotech, Inc. | Synthesis and antiviral evaluation of nucleic acid based (nab) libraries |
| WO2006063149A1 (en) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| BRPI1004575A2 (pt) | 2009-01-09 | 2016-04-05 | Inhibitex Inc | composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo |
| US20120070411A1 (en) | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| US9156874B2 (en) * | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| DK3031812T3 (en) * | 2011-03-01 | 2018-09-17 | NuCana plc | CHEMICAL COMPOUNDS |
| EP2697242B1 (en) * | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| AU2014354775A1 (en) | 2013-11-27 | 2016-05-19 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of liver cancer |
| CA2947939A1 (en) * | 2014-05-28 | 2015-12-03 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| KR102421929B1 (ko) | 2014-06-25 | 2022-07-15 | 뉴카나 피엘씨 | 젬시타빈-전구 약물 함유 제제 |
| IL291927A (en) * | 2014-11-28 | 2022-06-01 | NuCana plc | Oligonucleotides containing modified nucleosides |
| US10106501B2 (en) | 2015-06-09 | 2018-10-23 | Abbvie Inc. | Nuclear receptor modulators |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
-
2016
- 2016-06-01 GB GBGB1609601.8A patent/GB201609601D0/en not_active Ceased
-
2017
- 2017-05-31 EA EA201892745A patent/EA036409B1/ru unknown
- 2017-05-31 JP JP2018563085A patent/JP7025351B2/ja active Active
- 2017-05-31 ES ES17728596T patent/ES2801448T3/es active Active
- 2017-05-31 DK DK17728596.2T patent/DK3464309T3/da active
- 2017-05-31 SI SI201730308T patent/SI3464309T1/sl unknown
- 2017-05-31 HU HUE17728596A patent/HUE051335T2/hu unknown
- 2017-05-31 CN CN201780033787.3A patent/CN109195981A/zh active Pending
- 2017-05-31 WO PCT/GB2017/051549 patent/WO2017207986A1/en unknown
- 2017-05-31 MY MYPI2018002148A patent/MY198880A/en unknown
- 2017-05-31 BR BR112018074961-3A patent/BR112018074961A2/pt not_active Application Discontinuation
- 2017-05-31 PT PT177285962T patent/PT3464309T/pt unknown
- 2017-05-31 MX MX2018014859A patent/MX2018014859A/es unknown
- 2017-05-31 CA CA3025440A patent/CA3025440A1/en active Pending
- 2017-05-31 EP EP17728596.2A patent/EP3464309B1/en active Active
- 2017-05-31 US US16/305,153 patent/US10906929B2/en active Active
- 2017-05-31 AU AU2017273117A patent/AU2017273117B2/en active Active
- 2017-05-31 KR KR1020187037518A patent/KR20190015353A/ko active IP Right Grant
- 2017-05-31 PL PL17728596T patent/PL3464309T3/pl unknown
- 2017-05-31 SG SG11201810018TA patent/SG11201810018TA/en unknown
-
2018
- 2018-11-14 ZA ZA2018/07652A patent/ZA201807652B/en unknown
- 2018-11-19 IL IL263121A patent/IL263121B/en unknown
- 2018-11-26 PH PH12018502606A patent/PH12018502606A1/en unknown
- 2018-11-29 SA SA518400552A patent/SA518400552B1/ar unknown
- 2018-11-29 CL CL2018003404A patent/CL2018003404A1/es unknown
-
2020
- 2020-06-19 HR HRP20200983TT patent/HRP20200983T1/hr unknown
-
2021
- 2021-01-06 US US17/142,936 patent/US20210130387A1/en not_active Abandoned
-
2022
- 2022-02-10 JP JP2022019417A patent/JP2022051936A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| SG11201810146SA (en) | Adenosine derivatives for use in the treatment of cancer | |
| SG11201906223TA (en) | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201806700RA (en) | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201805318SA (en) | Formulations of phosphoramidate derivatives of nucleoside drugs | |
| SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201810196RA (en) | Cancer treatments | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201805184TA (en) | Combination therapy | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |